Having shipped its first benchtop gene editing devices, Inscripta draws another $150M from deep investor well
Inscripta is one big step closer to reaching its ambitious vision of vastly scaling and democratizing access to gene editing. And investors have thrown in $150 million more to join the ride.
The first batch of Onyx, its benchtop system for genome engineering, has been shipped to customers, the company said, enabling scientists to conduct automated high-throughput gene editing on a machine about the size of a microwave.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.